IDRA
$2.20
Idera Pharmaceutical
($.02)
(.90%)
IDRA
Earnings Whisper ®
N/A
3rd Quarter September 2017
Consensus:  ($0.12)
Revenue:  $0.20 Mil
Monday
Nov 6
Before the open
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when IDRA reports earnings?
Beat
Meet
Miss

Where is IDRA's stock price going from here?
Up
Flat
Down
Stock chart of IDRA
Analysts
Summary of analysts' recommendations for IDRA
Score
Grade
Pivots
Resistance
$2.54
$2.45
$2.33

$2.24

Support
$2.12
$2.03
$1.91
Tweet
Growth
Description
Idera Pharmaceuticals, Inc. is a drug discovery and development company that is developing drug candidates to treat cancer and infectious, respiratory, and autoimmune diseases, and for use in combination with therapeutic and prophylactic vaccines. Idera's proprietary drug candidates are designed to modulate Toll-like Receptors, the body's first line of immune defense. Idera's pioneering DNA chemistry expertise enables it to identify drug candidates for internal development and creates opportunities for multiple collaborative alliances.
Peers
BiogenGilead SciencesAmgenBluebird BioSeattle GeneticsNeurocrine BiosciencesJuno TherapeuticsQiagen N.V.BioCryst PharmaceuticalsBio-Techne